EGFR and non-small cell lung carcinoma: This paradigm began with the use of osimertinib to overcome the EGFR exon 20 p.T790M mutation in EGFR-mutant NSCLC, where outcomes were similarly favorable in patients with p.T790M detected in tissue or liquid biopsy [34].